Specific inhibitors of upregulated kinases and interconnected signaling pathways can be potential therapeutics of COVID-19 such as pictilisib (inhibitor of PI3K), omipalisib (inhibitor of PI3K and mTOR), sorafenib (inhibits growth factor receptor and RAF), RO5126766 [inhibits both mitogen-activated protein kinase (MAP2K2 or MEK) and the RAF], gilteritinib (inhibitor of FLT3 and AXL), ipatasertib (AKT inhibitor), prinomastat (specific inhibitor of MMP2), and marimastat (specific inhibitor of MMP9). This evidence concerns the gene AKT1 and COVID-19.